KB004 is a first-in-class, monoclonal antibody targeting the EphA3 receptor tyrosine kinase created using KaloBios’ proprietary Humaneered technology (Company Pipeline, KaloBios, JUL 4, 2016, View Source [SID:1234513678]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

KB004 is unique in its potential to attack tumors at their source by killing tumor cells, tumor stromal cells that protect them, and the vasculature that feeds them without killing normal cells. This unique combination of activities may provide the potential to generate durable responses. KB004 may have a similar mechanism of action in patients with solid tumors since it targets solid tumor stem cells and their microenvironment.